Literature DB >> 22194420

The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease.

Sarah A Ingersoll1, Saravanan Ayyadurai, Moiz A Charania, Hamed Laroui, Yutao Yan, Didier Merlin.   

Abstract

Intestinal inflammation is characterized by epithelial disruption, leading to loss of barrier function and the recruitment of immune cells, including neutrophils. Although the mechanisms are not yet completely understood, interactions between environmental and immunological factors are thought to be critical in the initiation and progression of intestinal inflammation. In recent years, it has become apparent that the di/tripeptide transporter PepT1 may play an important role in the pathogenesis of such inflammation. In healthy individuals, PepT1 is primarily expressed in the small intestine and transports di/tripeptides for metabolic purposes. However, during chronic inflammation such as that associated with inflammatory bowel disease, PepT1 expression is upregulated in the colon, wherein the protein is normally expressed either minimally or not at all. Several recent studies have shown that PepT1 binds to and transports various bacterial di/tripeptides into colon cells, leading to activation of downstream proinflammatory responses via peptide interactions with innate immune receptors. In the present review, we examine the relationship between colonic PepT1-mediated peptide transport in the colon and activation of innate immune responses during disease. It is important to understand the mechanisms of PepT1 action during chronic intestinal inflammation to develop future therapies addressing inappropriate immune activation in the colon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194420      PMCID: PMC3311434          DOI: 10.1152/ajpgi.00477.2011

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  81 in total

1.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

Review 2.  The oligopeptide transporter (Pept-1) in human intestine: biology and function.

Authors:  S A Adibi
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

3.  Immuno-localization of H+/peptide cotransporter in rat digestive tract.

Authors:  H Ogihara; H Saito; B C Shin; T Terado; S Takenoshita; Y Nagamachi; K Inui; K Takata
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

4.  Expression cloning of a mammalian proton-coupled oligopeptide transporter.

Authors:  Y J Fei; Y Kanai; S Nussberger; V Ganapathy; F H Leibach; M F Romero; S K Singh; W F Boron; M A Hediger
Journal:  Nature       Date:  1994-04-07       Impact factor: 49.962

5.  Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.

Authors:  M E Hiltz; J M Lipton
Journal:  FASEB J       Date:  1989-09       Impact factor: 5.191

6.  Lactobacillus casei alters hPEPT1-mediated glycylsarcosine uptake in Caco-2 cells.

Authors:  Brien L Neudeck; Jennifer M Loeb; Nancy G Faith
Journal:  J Nutr       Date:  2004-05       Impact factor: 4.798

7.  Expression and protein kinase C-dependent regulation of peptide/H+ co-transport system in the Caco-2 human colon carcinoma cell line.

Authors:  M Brandsch; Y Miyamoto; V Ganapathy; F H Leibach
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

8.  Transepithelial glycylsarcosine transport in intestinal Caco-2 cells mediated by expression of H(+)-coupled carriers at both apical and basal membranes.

Authors:  D T Thwaites; C D Brown; B H Hirst; N L Simmons
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

9.  Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.

Authors:  R Liang; Y J Fei; P D Prasad; S Ramamoorthy; H Han; T L Yang-Feng; M A Hediger; V Ganapathy; F H Leibach
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

10.  Effect of bestatin on syngeneic tumors in mice.

Authors:  F Abe; K Shibuya; M Uchida; K Takahashi; H Horinishi; A Matsuda; M Ishizuka; T Takeuchi; H Umezawa
Journal:  Gan       Date:  1984-01
View more
  36 in total

Review 1.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

2.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Epithelial transport in inflammatory bowel diseases.

Authors:  Fayez K Ghishan; Pawel R Kiela
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

4.  Establishment of immortalized mouse intestinal epithelial cells line and study of effects of Arg-Arg on inflammatory response.

Authors:  Kang Zhan; Maocheng Jiang; Yannan Sui; Kang Yan; Miao Lin; Guoqi Zhao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-03-24       Impact factor: 2.416

Review 5.  Chemically modified peptides and proteins - critical considerations for oral delivery.

Authors:  Stephen T Buckley; František Hubálek; Ulrik Lytt Rahbek
Journal:  Tissue Barriers       Date:  2016-03-03

Review 6.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

Review 7.  Butyrate: A Double-Edged Sword for Health?

Authors:  Hu Liu; Ji Wang; Ting He; Sage Becker; Guolong Zhang; Defa Li; Xi Ma
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

8.  Clinical relevance of intestinal peptide uptake.

Authors:  Hugh James Freeman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-05-06

9.  Plasma concentrations and ACE-inhibitory effects of tryptophan-containing peptides from whey protein hydrolysate in healthy volunteers.

Authors:  Melanie Martin; Diana Hagemann; Thinh Trung Nguyen; Lisa Schwarz; Sherif Khedr; Mats Leif Moskopp; Thomas Henle; Andreas Deussen
Journal:  Eur J Nutr       Date:  2019-05-03       Impact factor: 5.614

10.  Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide.

Authors:  Shu-Pei Wu; David E Smith
Journal:  Mol Pharm       Date:  2013-01-07       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.